Will the final 2027 CMS Medicare Advantage rate notice come in below medical cost trend?

CMS has a well-established pattern where the final rate notice closely tracks the advance notice with modest adjustments. The advance notice was below medical cost trend, and historically CMS makes minor upward revisions in the final but rarely large ones. The current fiscal environment favors spending restraint, and CMS has been consistently pressuring MA plan economics through Stars reforms, V28, and rate-setting. With medical cost trend running at 'higher end mid-single digit,' a rate increase below 4.5% is plausible given that CMS's stated trend estimates often differ from industry estimates. Probability moderately favors below-trend final.

The advance rate notice provides a strong prior for the final. CMS typically adjusts upward by 0-100bps from advance to final, reflecting public comment feedback. However, the political dynamics around Medicare Advantage are complex — Congress has historically pressured CMS to support MA plans, and the industry lobbying infrastructure is formidable. The 4.5% threshold aligns roughly with where advance was. If CMS maintains its advance estimate with minimal upward revision, the final would be below trend. If the comment period produces meaningful upward revision, it could cross above 4.5%. Slight lean toward below-trend based on advance notice signal.

Historical pattern analysis: over the past decade, CMS final rate notices have come in at or modestly above the advance notice approximately 90% of the time. The advance was below trend, which sets a strong base case. However, the definition of 'below medical cost trend' is inherently subjective — CMS's own actuarial analysis often shows lower cost trends than industry estimates, allowing CMS to claim the rate is adequate while the industry calls it below-trend. If CMS's own trend estimate is 4.0% and they set rates at 4.2%, CMS calls it above-trend while industry calls it below. This definitional ambiguity pushes probability modestly higher for YES.

The advance rate notice being below trend is a strong predictive signal for the final. CMS's recent pattern has been to pressure MA plan economics — V28, Stars reforms, and rate-setting all point toward tighter funding. The current administration has shown willingness to implement cost controls. The 4.5% threshold is the key question: medical cost trend is running 'higher end mid-single digit' (presumably 6-7%), so even a rate increase of 4-4.5% would be below trend. CMS is unlikely to provide a rate increase that fully matches industry-estimated cost trends. Moderate probability of YES.

CMS has structural incentives to keep MA rates below medical cost trend growth — it saves the Medicare Trust Fund money and creates pressure on MA plans to be more efficient. The advance notice already signals this direction. Congressional pressure to support MA typically manifests in preventing rate CUTS, not ensuring rates match cost trend. With Humana and UnitedHealth both flagging rate adequacy concerns, the industry narrative is clearly preparing for a below-trend outcome. CEO Rechtin's explicit language about 'adapting to the funding environment' suggests Humana's internal modeling expects below-trend.

Two countervailing forces: (1) CMS's advance notice and general policy direction favor below-trend rates, and (2) the industry lobbying response and potential political pressure could push the final notice marginally higher. Historical data shows the final rate is typically within 50-100bps of the advance. Given that the advance was already below trend, the final would need a significant positive revision to cross above 4.5%. Such large revisions are uncommon but not unprecedented. The probability leans toward below-trend but with meaningful uncertainty about the exact magnitude.

Advance notice below trend sets strong base case. CMS finals track advance closely. Medical cost trends running 6-7% while rates likely 4-4.5%. Moderate probability that final remains below trend.

The advance notice is below trend but CMS has occasionally provided meaningful upward revisions in the final. Industry lobbying is intense this cycle given the triple squeeze on MA economics. There's a real possibility of modest upward revision that could push the rate closer to trend. Still, the base case favors below-trend.

CMS has been consistently tightening MA economics across multiple vectors. The advance notice below trend is not an anomaly but part of a deliberate policy pattern. Medical cost trends are running well above the likely rate increase. The final will likely track the advance with minor upward adjustment, but still below the industry-estimated cost trend of 6-7%.